COCHRANE SERIES, PART 3 – DEEP DIVE: False alarm. The Cochrane Review shook confidence in Leqembi. It rests on a scientific threshold its own source publicly disowned. Here’s why the evidence did not justify the alarm.
COCHRANE SERIES, PART 2 – HOW IT HAPPENED: A new review just went viral in the media, declaring Alzheimer’s drugs don’t work. Leading scientists say the methodology was fundamentally flawed.
COCHRANE SERIES, PART 1 – WHAT HAPPENED:
A respected review called a breakthrough Alzheimer’s drug useless. Experts shrugged. Investors, who normally panic on such news, barely noticed. Here’s why that matters — and what it means for families weighing
In a new deal with Alloy Therapeutics, Biogen—the makers of Leqembi—is investing in RNA technology that could point toward what comes next in Alzheimer’s care.
Could Leqembi be given faster and more easily in the future? The new Biogen–Alteogen deal suggests it’s possible—but it doesn’t confirm changes to Leqembi. Here’s what professionals and families should understand.
The diagnostic and treatment network behind Leqembi may be its biggest competitive edge.
New research reveals that Leqembi’s Fc region switches on microglia — the brain’s immune cells — helping them clear toxic amyloid. Here’s why that mechanism matters for treatment and safety.
Many diagnosed patients won’t qualify — here are the
7 medical criteria.
In a one-hour seminar, a leading neurologist answers the most important questions families ask about what these new therapies can realistically deliver — from effectiveness and safety to eligibility, infusion logistics, cost, and access.
New evidence suggests genetics—not geography—may explain why Leqembi causes fewer ARIA brain side effects in parts of Asia, and what that means for families everywhere.